The phase 1/2b clinical trial on R21/Matrix-M malaria vaccine has recently reported the safety and efficacy of booster vaccination at 12 months. The entire report has been published in The Lancet ...

The R21/Matrix-M™ malaria vaccine is one step closer to mass rollout, after officially receiving WHO prequalification status, making it eligible for procurement by United Nations agencies. • ...

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...

Go to source) This vaccine was developed through a partnership between the Serum Institute of India (SII) in Pune //and the University of Oxford in the UK. In 2021,the RTS,S/AS01 vaccine became the ...

FILE PHOTO: A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya.(REUTERS) The R21/Matrix-M malaria vaccine developed ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious ...

Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine. A full 12-month commercial cycle under Sanofi’s control ...

Q4 2025 Management View John Jacobs, President and CEO, stated that "we made significant progress on our corporate strategy in 2025, successfully executing against our existing partnerships while ...

Vaccines manufacturer Serum Institute of India (SII) on Monday said it has started exports of 'R21/Matrix-M' malaria vaccine to Africa as part of the global fight against the disease. Developed in ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...